`
`
`
`DEPARTMENT OF HEALTH AND HUMAN SERVICES
`
`
`
`
`
`
` NDA 202343/S-010
`
`
`
`
`
`
`
`
`Food and Drug Administration
`
`
` Silver Spring MD 20993
`
`SUPPLEMENT APPROVAL
`
`
`
`
`
`
`
` Merck Sharp & Dohme Corp.
`
` Attention: Lou Ann Eader, Ph.D.
`
` Director, Worldwide Regulatory Affairs
`
` 351 N. Sumneytown Pike, P. O. Box 1000
`
`
`UG2CD-48
` North Wales, PA 19454-1099
`
`
`
`Dear Dr. Eader:
`
`
`
`
`
`
`
`Please refer to your Supplemental New Drug Application (sNDA) dated and received
`
`
`
`May 31, 2013, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act
`
`
`(FDCA) for Juvisync (sitagliptin and simvastatin) 100 mg/10 mg, 100 mg/20 mg, and
`
`
`100 mg/40 mg tablets.
`
`
`
`
`
`
`This “Prior Approval” supplemental new drug application proposes deletion of text in the Initial
`
`
`Combination Therapy with Metformin subsection of Section 14.1 that describes results from an
`
`
`open-label treatment arm of the study. This revision was made in response to our April 26, 2013,
`
`
`
`letter requesting that such information be removed from the Package Insert.
`
`
`APPROVAL & LABELING
`
`We have completed our review of this supplemental application. It is approved, effective on the
`
`
`
`
`date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.
`
`
`WAIVER OF HIGHLIGHTS SECTION
`
`
`Please note that we have previously granted a waiver of the requirements of 21 CFR
`
`
`
`
`201.57(d)(8) regarding the length of Highlights of prescribing information.
`
`
`
`
`CONTENT OF LABELING
`
`
`
`As soon as possible, but no later than 14 days from the date of this letter, submit the content of
`
`
`labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA
`
`
`
`
`
`automated drug registration and listing system (eLIST), as described at
`
`http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content
`
`
`of labeling must be identical to the enclosed labeling (text for the package insert, text for the
`
`
`patient package insert, Medication Guide), with the addition of any labeling changes in pending
`
`
`“Changes Being Effected” (CBE) supplements, as well as annual reportable changes not
`
`
`
`included in the enclosed labeling.
`
`
`Reference ID: 3359746
`
`

`

`
`
`
`
`
`
`Sincerely,
`
`
`{See appended electronic signature page}
`
`
`Mary H. Parks, M.D.
`
`Director
`
`Division of Metabolism and Endocrinology Products
`
`Office of Drug Evaluation II
`
`
`Center for Drug Evaluation and Research
`
`
` NDA 202343/S-010
`
` Page 2
`
`
`
`
`
` Information on submitting SPL files using eList may be found in the guidance for industry titled
` “SPL Standard for Content of Labeling Technical Qs and As at
`
`
`
`http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/U
`CM072392.pdf.
`
`
`The SPL will be accessible from publicly available labeling repositories.
`
`
`
`
`
` Also within 14 days, amend all pending supplemental applications that includes labeling changes
`
` for this NDA, including CBE supplements for which FDA has not yet issued an action letter,
`
`
` with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the
`
`
`
`
`
` changes approved in this supplemental application, as well as annual reportable changes and
`
` annotate each change. To facilitate review of your submission, provide a highlighted or marked-
`
`
`
` up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy
`
`
`
`
`
`
`
` should provide appropriate annotations, including supplement number(s) and annual report
`date(s).
`
`
`REPORTING REQUIREMENTS
`
`
`We remind you that you must comply with reporting requirements for an approved NDA
`
`
`
`(21 CFR 314.80 and 314.81).
`
`
`
`If you have any questions, call Richard Whitehead, Regulatory Project Manager, at
`
`
`
`(301) 796-4945.
`
`
`
`
`
`
`ENCLOSURES:
`
`Content of Labeling
`
`
`Package Insert
`
`Medication Guide
`
`
`
`
`Reference ID: 3359746
`
`

`

`---------------------------------------------------------------------------------------------------------
`This is a representation of an electronic record that was signed
`electronically and this page is the manifestation of the electronic
`signature.
`---------------------------------------------------------------------------------------------------------
`/s/
`----------------------------------------------------
`
`MARY H PARKS
`08/19/2013
`
`Reference ID: 3359746
`
`